[ad_1]
AUSTIN, Texas – (BUSINESS WIRE) – Nov. November 2021–
Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced today that its management team will be presenting at the following health conferences:
- Piper Sandler 33rd Annual Virtual Healthcare Conference: A recorded webcast of the presentation will be available starting November 22, 2021 at 10:00 a.m. ET / 7:00 a.m. PT.
- Evercore ISI 4th Annual HealthCONx Virtual Conference: A live webcast of a fireplace chat will be held on November 30, 2021 at 8:50 a.m. ET / 5:50 a.m. PT.
Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, Molgramostim Nebulizer Solution, is an inhaled granulocyte macrophage colony stimulating factor (GM-CSF) in phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is administered via an eFlow® nebulizer system (PARI Pharma GmbH) that is currently being tested. Our management team has extensive experience in rare respiratory diseases and pulmonary medicine, identifies unmet needs and effectively advances product candidates to approval and commercialization. More information is available at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).
CONTACT: Savara Inc. IR & PR
Senior Vice President, Chief of Staff
KEYWORD: UNITED STATES NORTH AMERICA TEXAS
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH CLINICAL STUDIES
Copyright Business Wire 2021.
PUB: 11/15/2021 8:05 am / DISC: 11/15/2021 8:05 am
Copyright Business Wire 2021.
[ad_2]
https://www.citizentribune.com/news/business/savara-to-participate-in-two-upcoming-investor-healthcare-conferences/article_04ecde43-bce4-53b7-aaaf-410fb3384a50.html
